Our journey began in the academic laboratories of Queen Mary University of London and the University of Bristol, where our founding team pioneered novel methods for cell separation and expansion. Recognising the potential to transform how patient-specific treatments are manufactured, we spun out the technology and were incorporated as part of the inaugural Science Creates Accelerator. This early support was instrumental in refining our mission: to replace complex, costly manufacturing processes with a streamlined platform that makes tumour-targeted cell therapies safe, effective, and affordable for healthcare systems worldwide.

Since our incorporation, we have rapidly validated our technology clinical and commercial opportunity through some of the UK’s most prestigious innovation programmes. These include Impulse Programme at Cambridge University supported by Cancer Research Horizon. We successfully completed Phases I and II of the Cancer Tech Accelerator—backed by Cancer Research UK and Capital Enterprise, which cemented our focus on solving critical bottlenecks in CAR-T therapy production. Now in 2026, as we enter the final phase of the Future Medicines Accelerator, we have established our new headquarters at the Cardiff Medicentre on the Heath Park campus. Here, in collaboration with Cardiff University, we are scaling our Column of Expansion and Differentiation (CoED) platform to bring the next generation of cancer medicines to patients faster than ever before.